Rapalogix Health has established a dedicated research laboratory at Princeton Innovation Center BioLabs in Princeton, New Jersey.
According to the company, the facility expands the company’s internal research capabilities and will serve as the primary site for its translational research program into next-generation rapalogs, the proprietary compound class behind Re-Q Health, the company’s professional skincare brand.
The incubator, operated by BioLabs and founded by Princeton University, is a 30,000-square-foot facility with fully equipped wet and dry laboratory space, shared scientific equipment, and on-site technical staff that enables resident research to begin immediately.
The company claims its research team will use 2D, 3D and complex model systems to study longevity pathways in skin biology, characterize mechanisms of action across its rapalog portfolio, evaluate novel formulations, and generate proprietary data to support future product development.
The work builds on RLX-201, Rapalogix’s proprietary longevity molecule and the active compound in Re-Q Longevity Face Serum, and the laboratory became operational on 17 August 2026.
